A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,200 shares of DMAC stock, worth $36,736. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,200
Previous 1,300 530.77%
Holding current value
$36,736
Previous $3,000 1033.33%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.8 - $4.49 $9,570 - $15,346
3,418 Added 40.63%
11,831 $49,000
Q2 2024

Aug 14, 2024

SELL
$2.16 - $3.66 $33,711 - $57,121
-15,607 Reduced 64.98%
8,413 $24,000
Q1 2024

May 15, 2024

BUY
$2.58 - $3.23 $3,366 - $4,215
1,305 Added 5.75%
24,020 $66,000
Q4 2023

Feb 14, 2024

BUY
$2.05 - $2.99 $14,036 - $20,472
6,847 Added 43.15%
22,715 $64,000
Q3 2023

Nov 14, 2023

BUY
$2.56 - $4.4 $20,367 - $35,006
7,956 Added 100.56%
15,868 $40,000
Q2 2023

Aug 14, 2023

SELL
$1.53 - $4.4 $52,512 - $151,016
-34,322 Reduced 81.27%
7,912 $34,000
Q1 2023

May 15, 2023

BUY
$1.32 - $1.89 $3,983 - $5,704
3,018 Added 7.7%
42,234 $64,000
Q4 2022

Feb 14, 2023

BUY
$1.13 - $1.62 $4,863 - $6,972
4,304 Added 12.33%
39,216 $61,000
Q3 2022

Nov 14, 2022

BUY
$1.2 - $2.07 $20,280 - $34,983
16,900 Added 93.83%
34,912 $43,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $118M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.